Finally, Protagonist Therapeutics (NASDAQ:PTGX) has indicated that its financial runway extends beyond the fourth quarter of 2028, providing the company with a stable foundation to continue its ...
Akeso, Inc. (9926.HK) ("Akeso" or the "Company") is excited to announce that the prestigious medical journal Nature Medicine ...
After a Stage 4 cancer diagnosis and a prognosis of 16 months to live, Katie Doble didn’t know whether she should plan her ...
Collaboration to take Cytovation’s synthetic peptide, CY-101, into a Phase 2 trial for patients with adrenocortical carcinomaCancer Research UK’s Centre for Drug Development to run the trial at sites ...
NDAQ:ZLAB) Zai Lab Receives Orphan Drug Designation from the U.S. FDA for ZL-1310 (DLL3 ADC) for the Treatment of Small Cell ...
One of the earliest proponents of evidence-based medicine, Professor David Sackett, wrote, “Good doctors use both individual ...
Emil Kraepelin formulated the initial nosology of Alzheimer's disease in the first decade of the 20th century. Nowadays, clinical and pathological presentations (including those associated with ...
Celldex Therapeutics , Inc. (NASDAQ:CLDX), a biopharmaceutical company with a market capitalization of $1.6 billion focused on developing innovative therapies for challenging diseases, has been making ...
Nuvalent, Inc. shares have fallen approximately 30% after promising updates on its two lead NSCLC candidates rallied the ...
Segal Trials, a privately held clinical research network specializing in acute schizophrenia and other psychiatric disorders, ...
In an interview, Danielle Mitchell of BWICR discussed the importance of increasing diversity in clinical research and making ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback